1. Review the results of a double-blind, randomized trial that assigns patients with type 2 diabetes and albuminuric chronic kidney disease doses of canagliflozin.
2. Look at broader implications
Thursday, May 2, 2019 - 1:00pm to 2:00pm
Saurabh Chawla, MD
Chicago, IL 60637
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation